the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04521400

Recruitment Status : Not yet recruiting

First Posted : August 20, 2020

Last Update Posted : August 20, 2020

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Ilad Alavi Darazam, Shahid Beheshti University of Medical Sciences

Study Description

Brief Summary:

The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

Condition or disease	Intervention/treatment	Phase
Covid19	Drug: High dose Interferon-beta 1a Drug: Lopinavir/Ritonavir Drug: Low dose Interferon-beta 1a	Phase 2

Detailed Description:

According to previous studies, IFN-β has strong antiviral activity and also has an acceptable safety profile. Based on possible therapeutic effects, we decided to lead an Investigation into Beneficial Effects of high-dose Interferon Beta 1a, Compared to low-dose Interferon Beta 1a (the base therapeutic regimen) in Moderate to Severe COVID-19.

Previous studies demonstrate that IFN-β 1a could be used against some coronaviruses including avium infectious, bronchitis virus, murine hepatitis virus, and SARS- CoV because they are susceptible in vitro or in vivo. In a current study, the efficacy of IFN-β 1a in COVID-19 patients were evaluated, and they found than IFN-β 1a reduced the disease symptoms.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	100 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19
Estimated Study Start Date :	August 20, 2020
Estimated Primary Completion Date :	September 4, 2020
Estimated Study Completion Date :	September 11, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Interferon Interferon beta Interferon beta-1a Ritonavir Lopinavir Avonex

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm1 Lopinavir /Ritonavir +high dose Interferon-β 1a	Drug: High dose Interferon-beta 1a High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6) Drug: Lopinavir/Ritonavir Lopinavir/Ritonavir (Kaletra) [IFN-β1a group] (400mg/100 mg twice a day for 10 days
Experimental: Arm2 Lopinavir /Ritonavir + Low dose Interferon-β 1a	Drug: Lopinavir/Ritonavir Lopinavir/Ritonavir (Kaletra) [IFN-β1a group] (400mg/100 mg twice a day for 10 days Drug: Low dose Interferon-beta 1a Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)

Outcome Measures

Primary Outcome Measures :

Time to clinical improvement [ Time Frame: From date of randomization until 14 days later ]
Improvement of two points on a seven-category ordinal scale (recommended by the World Health Organization: Coronavirus disease (COVID-2019) R&D. Geneva: World Health Organization) or discharge from the hospital, whichever came first.

Secondary Outcome Measures :

Mortality [ Time Frame: From date of randomization until 14 days later ]
If the patient dies, we have reached an outcome
SpO2 Improvement [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7 and 14 ]
Pulse-oxymetry
Incidence of new mechanical ventilation use [ Time Frame: From date of randomization until 14 days later ]
Duration of hospitalization [ Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 14 days ]
Cumulative incidence of serious adverse events [ Time Frame: Days 1, 2, 3, 4, 5, 6, 7 and 14 ]
With the incidence of any serious adverse effects, the outcome has happened

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 100 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Age ≥ 18
COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed)
at least one of the following: radiation contactless body temperature ≥37.5, cough, shortness of breath, nasal congestion/ discharge, myalgia/arthralgia, diarrhea/vomiting, headache or fatigue on admission.
Time of onset of the symptoms should be acute (Days ≤ 14)
NEWS2 ≥ 1 on admission (National Early Warning Score 2)

Exclusion Criteria:

Refusal to participate expressed by patient or legally authorized representative if they are present
Patients using drugs with potential interaction with Lopinavir/Ritonavir or Interferon-β 1a
Pregnant or lactating women.
History of alcohol or drug addiction in the past 5 years.
Blood ALT/AST levels > 5 times the upper limit of normal on laboratory results.
The patients who were intubated less than one hours after admission to the hospital

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04521400

Contacts

Layout table for location contacts

Contact: Ilad Alavi Darazam, MD	+98-914-149-1958	ilad13@yahoo.com

Sponsors and Collaborators

Shahid Beheshti University of Medical Sciences

Investigators

Layout table for investigator information

Study Chair:	Ilad Alavi Darazam, M.D	Shahid Beheshti University of Medical Sciences
Principal Investigator:	Firouze Hatami, M.D	Shahid Beheshti University of Medical Sciences
Principal Investigator:	Mohammad Mahdi Rabiei, M.D	Shahid Beheshti University of Medical Sciences
Principal Investigator:	Omid Moradi	Shahid Beheshti University of Medical Sciences
Principal Investigator:	Behnam Rahimi, M.D	Shahid Beheshti University of Medical Sciences
Study Director:	Shervin Shokouhi, M.D	Shahid Beheshti University of Medical Sciences
Principal Investigator:	Mohammad Reza Hajesmaeili, M.D	Shahid Beheshti University of Medical Sciences
Principal Investigator:	Minoosh Shabani, M.D	Shahid Beheshti University of Medical Sciences
Principal Investigator:	Seyed Sina Naghibi Irvani, M.D	Shahid Beheshti University of Medical Sciences

More Information

Publications:

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.

Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.

Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, Dong XQ, Zheng YT. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020 May;17(5):541-543. doi: 10.1038/s41423-020-0401-3. Epub 2020 Mar 17.

Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol. 2019 Jun;43:101300. doi: 10.1016/j.smim.2019.101300. Review.

Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.

Hensley LE, Fritz LE, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis. 2004 Feb;10(2):317-9.

Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, Hashemian SM, Baghaei P, Abedini A, Varahram M, Yousefian S, Tabarsi P. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug;85:106688. doi: 10.1016/j.intimp.2020.106688. Epub 2020 Jun 7.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Alavi Darazam I, Hatami F, Rabiei MM, Pourhoseingholi MA, Moradi O, Shokouhi S, Hajesmaeili MR, Shabani M, Irvani SSN. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. Trials. 2020 Oct 26;21(1):880. doi: 10.1186/s13063-020-04812-2.

Layout table for additonal information

Responsible Party:	Ilad Alavi Darazam, Dr. Ilad Alavi Darazam, MD, Shahid Beheshti University of Medical Sciences
ClinicalTrials.gov Identifier:	NCT04521400
Other Study ID Numbers:	Interferon in COVID
First Posted:	August 20, 2020 Key Record Dates
Last Update Posted:	August 20, 2020
Last Verified:	August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Ilad Alavi Darazam, Shahid Beheshti University of Medical Sciences:


COVID-19 Interferons Ritonavir Lopinavir	Interferon-beta Antiviral Agents Anti-Infective Agents Immunologic Factors

Additional relevant MeSH terms:

Layout table for MeSH terms

Interferons Ritonavir Lopinavir Interferon-beta Interferon beta-1a Antineoplastic Agents Antiviral Agents Anti-Infective Agents HIV Protease Inhibitors Protease Inhibitors	Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Immunologic Factors Physiological Effects of Drugs Adjuvants, Immunologic

To Top